Member Info for B2HS2L

Can't imagine AS being very impressed having to explain what was appearing on the Medusa website via RNS.

Medusa are developing the website using the same address they intend for business use.

That's not something I've heard of, but a good way to ramp up interest from a standing start.

Is the Medusa website link available yet on BooHoo? - If not it soon will be.

Yes justdeezerts.

SNG001 to fix the problems caused by virus entering lung cells via ACE2.

AeroNabs to stop virus/ACE2 interaction.

AeroNabs will have to provide 100% protection (tall order) - else SNG001 will be necessary at which point, worst case, the virus has infected other major organs.

Thanks for the link.

Human trials "soon" for three part nanobodies.

https://www.sciencedaily.com/releases/2020/08/200811234951.htm

Experiments using live virus show that the molecule is among the most potent SARS-CoV-2 antivirals yet discovered.

https://www.biorxiv.org/content/10.1101/2020.08.08.238469v1

Excellent video here

https://www.youtube.com/watch?v=WjhbexLtYts&feature=youtu.be

Wishing them well on agreeing trial start dates.
If this is going to fail I hope it fails fast to stop us all living in hope.
If it succeeds we need this available soonest.

Trials not started yet but here is a heads up.
Human trials "soon" for three part nanobodies.

https://www.sciencedaily.com/releases/2020/08/200811234951.htm

Experiments using live virus show that the molecule is among the most potent SARS-CoV-2 antivirals yet discovered.

https://www.biorxiv.org/content/10.1101/2020.08.08.238469v1

Excellent video here

https://www.youtube.com/watch?v=WjhbexLtYts&feature=youtu.be

"but those that wait until the 6monthly financials should be in for a just reward".
Thanks Ghia.
Do we know for sure that we will have some feedback on the US sales at the 6 month point please?
This subject is at the heart of peoples misgivings about NCYT financial reporting, in that there is a big black hole where investors have no financial information about US sales at all.

On a different subject.
If NCYT were to invest in purchasing a product or company that would generate regular income beyond mid 2021, company valuations would be much easier to discuss & evaluate, with consequent good vibrations for the sp.
GM must have plans, so I hope they are similar to the above.

https://www.bruker.com/fileadmin/user_upload/8-PDF-Docs/Molecular_Diagnostics/1877216_FluoroType_SARS-CoV2plus_IVD_flyer_04-2020_ebook.pdf

Bottom of page 2 - "Please contact your local representative for availability in your country. Not for sale in the USA"

No usage (or approval) in USA will dent sales.

https://www.labmedica.com/covid-19/articles/294783679/bruker-launches-second-generation-fluorotype-sars-cov-2-plus-pcr-test.html

"The FluoroType SARS-CoV-2 plus assay can also be used with Bruker´s FluoroCycler XT real-time PCR system"

++++

Novacyt RNS 25.03.2020 - Global distribution agreement with Bruker for COVID-19 diagnostic test

extract:

"Novacyt's real-time polymerase chain reaction (PCR) COVID-2019 IVD-CE test is validated for use on Bruker-Hain Diagnostics' GenoXtract® automated nucleic acid extraction device and associated extraction kits. IT IS UNDER VALIDATION ON BRUKER'S NEW FLUOROCYCLER ® XT PCR INSTRUMENT, allowing Bruker to provide a full solution from automated extraction to result. Bruker has already initiated shipments of the Primerdesign test into Spain, France, Germany and UK."

Capitals are mine for emphasis.

More recent RNS's do not contain confirmation that the Novacyt assay validation has been successfuly completed.

++++

https://www.hain-lifescience.de/uploadfiles/file/produkte/geraete/FluoroCyclerXT/fc_xt_eng.pdf

Bruker may now have completed the validation of the Novacyt real-time polymerase chain reaction (PCR) COVID-2019 IVD-CE test on the Bruker FLUOROCYCLER ® XT PCR instrument.
So if a non-US lab has a FLUOROCYCLER ® XT PCR instrument, (believed to have been launched in 2019), they may have a choice of Novacyt or Bruker assay's.

If they only want to detect SARS-CoV2, and Novacyte assay is cheaper (?), they can choose the Novacyte assay.

Post a link please iceman, then we will have the same reference.

If the site developer(s) were not using the https://medusa19.com web address to develop and make constant changes on, we would be none the wiser would we?
1 They will publish more incorrect info this way.
2 They will publish accurate info that is not in the public domain.

These two concerns will make Al's ulcer play up I'm sure, and I would not be surprised if the website is inaccessible by tonight.

Is it possible they will advertise the LFT on BooHoo providing a link to medusa, and kick start sales that way?

mowzer, - It's very amateurish to develop a website using the actual web address you will eventually use.
Choose another name with which to develop the site.
As it is they appear to have given us sensitivity and specificity data for what appears to be a antibody type test that is not for sale yet.
Imagine if they made that mistake with the LFT stick, Alistair might burst a blood vessel..

infor25, - First reported yesterday I believe? :
Crocqman, 13 Aug 2020 15:42

Choo-Choo, Your first post and you managed to insert a link?
Normally you need to post 10 or 20 times before that is possible.

Earlier there was talk of which manufacturer made the Saliva Anti-body test.

I have not seen the following web page or its content discussed tonight, and feel it is relevant to Medusa's future intent.

Better access it quick before content changes or disappears!

https://medusa19.com/prelaunch-about/
About Medusa 19
Medusa 19 was established in 2020 by entrepreneurs Richard Hughes and Mahmud Kamani with the objective of rapidly building a Business to Consumer (B2C) point-of-care medical diagnostics business, ensuring employee safety and business continuity.

Medusa 19 has the exclusive distribution rights to directly deliver to consumers a saliva-based rapid test, currently under development by Avacta Group Plc, for the COVID-19 antigen, subject to regulatory approval. As such, its immediate priority is to invest in the necessary functions that will enable Avacta’s test to be rapidly and globally deployed once it becomes available. Longer-term, the Group’s objective is to entrench itself within the global medical supply chain, serving businesses and consumers worldwide with a range of tests and solutions that identify a variety of conditions, supporting health, well-being and business continuity throughout the globe.

+++++

The last paragraph outlines the future intent, - selling beyond the Avacta saliva based rapid test with a range of tests and solutions.

Perhaps he will insist on not wearing a mask and contract C-19.
Ironic, but he could be on his death bed winning the election race with the sympathy vote.

Manifesto, do you mean his brother has a C-19 diagnosis?
+++
What is the link please for this conference please?

Manifesto 13:38 -
"£1.2 M on AIM means someone has most likely had a nod"

Well if I were waiting for a nod, when I knew I was going to buy £1.2 M of shares, I wouldn't want that money 'invested' in the share for very long before an announcement.

I would want to risk the money for the least amount of time in case sp loops the loop before announcement, - no peace of mind.
Also, if the announcement did not materialise, - a very uncomfortable weekend is guaranteed..

So on the assumption that £1.2 Mil is a very large sum of money to the buyer, I don't think news is very far away at all.

Hi TOB, - Hoping you have more than pocket money invested here!

And another:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/103628Orig1s000rev.pdf

Sparkle, - This isn't the only supplier, but try this:
https://adisinsight.springer.com/drugs/800007022

I hear what you are saying, and I thought you would be saying it. - So other than an NDA, why are we still waiting for COPD findings please?